Genentech's Lunsumio VELO Gains FDA Approval As Subcutaneous Treatment Option For Relapsed Or Refractory Follicular Lymphoma

Benzinga·12/22/2025 06:53:53

語音播報

Lunsumio VELO reduces administration time from 2-4 hours to approximately one minute
Availability of Lunsumio VELO allows treatment aligned to people's clinical needs and personal preferences
Approval supported by data demonstrating compelling complete response rate in third-line or later follicular lymphoma, which typically becomes harder to treat after each relapse